Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.02 Thousand DKK | 99.94% |
| 2022 | -41.74 Million DKK | -80.91% |
| 2021 | -23.07 Million DKK | -119.09% |
| 2020 | -10.53 Million DKK | -12.76% |
| 2019 | -9.33 Million DKK | 25.95% |
| 2018 | -12.61 Million DKK | -31.9% |
| 2017 | -9.56 Million DKK | -977.9% |
| 2016 | -887 Thousand DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.57 Million DKK | -83494.3% |
| 2024 Q2 | -4.99 Million DKK | -39.53% |
| 2023 Q3 | -5.19 Million DKK | 41.56% |
| 2023 Q4 | -4279.00 DKK | 99.92% |
| 2023 FY | -27.02 Thousand DKK | 99.94% |
| 2023 Q1 | -8.67 Million DKK | -33.97% |
| 2023 Q2 | -8.88 Million DKK | -2.36% |
| 2022 Q4 | -6.47 Million DKK | 3.17% |
| 2022 FY | -41.74 Million DKK | -80.91% |
| 2022 Q3 | -6.68 Million DKK | 50.45% |
| 2022 Q2 | -13.49 Million DKK | 10.45% |
| 2022 Q1 | -15.07 Million DKK | -107.07% |
| 2021 Q4 | -7.28 Million DKK | 19.61% |
| 2021 Q3 | -9.05 Million DKK | -83.17% |
| 2021 Q2 | -4.94 Million DKK | -175.89% |
| 2021 FY | -23.07 Million DKK | -119.09% |
| 2021 Q1 | -1.79 Million DKK | 13.39% |
| 2020 Q1 | -2.39 Million DKK | 4.43% |
| 2020 Q2 | -3.01 Million DKK | -25.96% |
| 2020 Q3 | -3.06 Million DKK | -1.83% |
| 2020 FY | -10.53 Million DKK | -12.76% |
| 2020 Q4 | -2.06 Million DKK | 32.56% |
| 2019 Q4 | -2.5 Million DKK | -27.12% |
| 2019 FY | -9.33 Million DKK | 25.95% |
| 2019 Q3 | -1.96 Million DKK | 42.16% |
| 2019 Q2 | -3.4 Million DKK | -132.67% |
| 2019 Q1 | -1.46 Million DKK | 41.67% |
| 2018 Q3 | -3.69 Million DKK | -12.3% |
| 2018 FY | -12.61 Million DKK | -31.9% |
| 2018 Q4 | -2.5 Million DKK | 32.2% |
| 2018 Q1 | -3.11 Million DKK | 19.47% |
| 2018 Q2 | -3.29 Million DKK | -5.88% |
| 2017 FY | -9.56 Million DKK | -977.9% |
| 2017 Q1 | -1.21 Million DKK | -69.85% |
| 2017 Q3 | -2.45 Million DKK | -21.4% |
| 2017 Q4 | -3.86 Million DKK | -57.29% |
| 2017 Q2 | -2.02 Million DKK | -67.05% |
| 2016 Q4 | -713 Thousand DKK | -334.76% |
| 2016 Q2 | -5000.00 DKK | 0.0% |
| 2016 Q3 | -164 Thousand DKK | -3180.0% |
| 2016 FY | -887 Thousand DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -46.48 Million SEK | 99.942% |
| Biovica International AB (publ) | -126.07 Million SEK | 99.979% |
| Cantargia AB (publ) | -290.01 Million SEK | 99.991% |
| CombiGene AB (publ) | -36.3 Million SEK | 99.926% |
| Cyxone AB (publ) | -21.66 Million SEK | 99.875% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 99.766% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 99.842% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 99.974% |
| Fluicell AB (publ) | -26.87 Million SEK | 99.899% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 99.98% |
| Mendus AB (publ) | -100.65 Million SEK | 99.973% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 99.935% |
| I-Tech AB | 24.43 Million SEK | 100.111% |
| Intervacc AB (publ) | -93.57 Million SEK | 99.971% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 99.782% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 100.15% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 99.835% |
| OncoZenge AB (publ) | -15.9 Million SEK | 99.83% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 96.801% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 99.991% |
| Lipum AB (publ) | -37.25 Million SEK | 99.927% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 99.989% |
| Ziccum AB (publ) | -21.56 Million SEK | 99.875% |
| BioArctic AB (publ) | 252.64 Million SEK | 100.011% |
| Genovis AB (publ.) | 54.22 Million SEK | 100.05% |
| Camurus AB (publ) | 532.35 Million SEK | 100.005% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 99.985% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 99.951% |
| Aptahem AB (publ) | -10.1 Million SEK | 99.733% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 99.992% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 99.985% |
| Kancera AB (publ) | -65.04 Million SEK | 99.958% |
| Saniona AB (publ) | -81.06 Million SEK | 99.967% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 99.936% |
| AcouSort AB (publ) | -17.48 Million SEK | 99.845% |
| Xintela AB (publ) | -57.23 Million SEK | 99.953% |
| Abliva AB (publ) | -96.54 Million SEK | 99.972% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 99.229% |
| Amniotics AB (publ) | -29.07 Million SEK | 99.907% |
| 2cureX AB (publ) | -36.36 Million SEK | 99.926% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 99.815% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 99.993% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 99.997% |
| Biosergen AB | -27.26 Million SEK | 99.901% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 99.826% |
| Corline Biomedical AB | -1.78 Million SEK | 98.488% |
| NextCell Pharma AB | -43.17 Million SEK | 99.937% |
| Nanologica AB (publ) | -69.96 Million SEK | 99.961% |
| LIDDS AB (publ) | -40.67 Million SEK | 99.934% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 99.992% |
| BioInvent International AB (publ) | -369.94 Million SEK | 99.993% |
| SynAct Pharma AB | -224.49 Million SEK | 99.988% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 99.939% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 99.887% |
| Alzinova AB (publ) | -16.52 Million SEK | 99.836% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 99.976% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 99.989% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 99.577% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 99.977% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 99.866% |
| Simris Alg AB (publ) | -36.63 Million SEK | 99.926% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 99.982% |